Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint

Page standards status: Informative

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "6514",
  "meta" : {
    "versionId" : "1"
  },
  "language" : "en",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 6514</b></p><a name=\"6514\"> </a><a name=\"hc6514\"> </a><div style=\"display: inline-block; background-color: #fbffeb; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 1</p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"Evidence-6514.html\">Evidence Percentage of Participants With Clinical Recovery Within 14 Days After Randomization -  for Control in Nigella Sativa for COVID-19 OSF Preprint</a></p><p><b>identifier</b>: FEvIR Object Identifier/6514, <a href=\"http://terminology.hl7.org/7.5.0/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.242</p><p><b>version</b>: 1.0.0-ballot3</p><p><b>name</b>: OSFPreprint_PrimaryOutcomeMeasure_0_OG001</p><p><b>title</b>: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization -  for Control in Nigella Sativa for COVID-19 OSF Preprint</p><p><b>status</b>: Active</p><p><b>date</b>: 2021-07-19 17:03:53+0000</p><p><b>author</b>: Brian S. Alper: </p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Control</p>\n</div><p><b>note</b>: </p><blockquote><div><p>control group within study population: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.</p>\n</div></blockquote><p><b>variableRole</b>: Population</p><p><b>observed</b>: standard of care medications alone</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-5269.html\">EvidenceVariable Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:\">Count of Participants</span></p><p><b>quantity</b>: 21 Participants</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>47</td></tr></table></blockquote></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code" : "active",
            "display" : "Active"
          }
        ]
      }
    }
  ],
  "url" : "https://fevir.net/resources/Evidence/6514",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net/FOI",
      "value" : "6514",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.4.642.40.44.22.242"
    }
  ],
  "version" : "1.0.0-ballot3",
  "name" : "OSFPreprint_PrimaryOutcomeMeasure_0_OG001",
  "title" : "Percentage of Participants With Clinical Recovery Within 14 Days After Randomization -  for Control in Nigella Sativa for COVID-19 OSF Preprint",
  "status" : "active",
  "date" : "2021-07-19T17:03:53.324Z",
  "author" : [
    {
      "name" : "Brian S. Alper"
    }
  ],
  "publisher" : "HL7 International / Clinical Decision Support",
  "contact" : [
    {
      "name" : "HL7 International / Clinical Decision Support",
      "telecom" : [
        {
          "system" : "url",
          "value" : "http://www.hl7.org/Special/committees/dss"
        }
      ]
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "variableDefinition" : [
    {
      "description" : "Control",
      "note" : [
        {
          "text" : "control group within study population: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia."
        }
      ],
      "variableRole" : "population",
      "observed" : {
        "display" : "standard of care medications alone"
      }
    },
    {
      "description" : "proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization",
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/5269",
        "type" : "EvidenceVariable"
      }
    }
  ],
  "statistic" : [
    {
      "description" : "There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).",
      "statisticType" : {
        "text" : "Count of Participants"
      },
      "quantity" : {
        "value" : 21,
        "unit" : "Participants"
      },
      "sampleSize" : {
        "knownDataCount" : 47
      }
    }
  ]
}